Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
AbbVie
Sotio Biotech Inc.
Carisma Therapeutics Inc
Zumutor Biologics Inc.
Taiho Pharmaceutical Co., Ltd.
Silverback Therapeutics
AstraZeneca